Home
>
National Drug Code (NDC)
>
Synagis
Synagis - 60574-4113-1 - (palivizumab)
Drug Information of Synagis
| Product NDC: | 60574-4113 |
| Proprietary Name: | Synagis |
| Non Proprietary Name: | palivizumab |
| Active Ingredient(s): | 100 mg/mL & nbsp; palivizumab |
| Administration Route(s): | INTRAMUSCULAR |
| Dosage Form(s): | INJECTION, SOLUTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Synagis
| Product NDC: | 60574-4113 |
| Labeler Name: | MedImmune, LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | BLA103770 |
| Marketing Category: | BLA |
| Start Marketing Date: | 19980619 |
Package Information of Synagis
| Package NDC: | 60574-4113-1 |
| Package Description: | 1 mL in 1 VIAL, SINGLE-DOSE (60574-4113-1) |
NDC Information of Synagis
| NDC Code | 60574-4113-1 |
| Proprietary Name | Synagis |
| Package Description | 1 mL in 1 VIAL, SINGLE-DOSE (60574-4113-1) |
| Product NDC | 60574-4113 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | palivizumab |
| Dosage Form Name | INJECTION, SOLUTION |
| Route Name | INTRAMUSCULAR |
| Start Marketing Date | 19980619 |
| Marketing Category Name | BLA |
| Labeler Name | MedImmune, LLC |
| Substance Name | PALIVIZUMAB |
| Strength Number | 100 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Antibodies, Monoclonal [Chemical/Ingredient],Fusion Protein Inhibitors [MoA],Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] |
